MX2016005680A - Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea. - Google Patents

Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea.

Info

Publication number
MX2016005680A
MX2016005680A MX2016005680A MX2016005680A MX2016005680A MX 2016005680 A MX2016005680 A MX 2016005680A MX 2016005680 A MX2016005680 A MX 2016005680A MX 2016005680 A MX2016005680 A MX 2016005680A MX 2016005680 A MX2016005680 A MX 2016005680A
Authority
MX
Mexico
Prior art keywords
endoplasmic reticulum
drug
cell death
therapeutic drug
diseases related
Prior art date
Application number
MX2016005680A
Other languages
English (en)
Inventor
Noriko Koizumi
Shigeru Kinoshita
Okumura Naoki
Original Assignee
Kyoto Prefectural Public Univ Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyoto Prefectural Public Univ Corp filed Critical Kyoto Prefectural Public Univ Corp
Publication of MX2016005680A publication Critical patent/MX2016005680A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility

Abstract

La presente invención provee un fármaco de tratamiento o fármaco profiláctico para enfermedades, trastornos, o condiciones relacionados con el estrés en el retículo endoplásmico (RE); específicamente, la presente invención provee un fármaco de tratamiento o fármaco profiláctico para enfermedades, trastornos, o condiciones relacionados con el estrés en el retículo endoplásmico (RE) de epitelio de córnea, el fármaco contiene un inhibidor de la señalización de TGFß; como un inhibidor de la señalización de TGFß preferido, el fármaco contiene 4-[4-(1,3-benzodioxol-5-il)-5-(2-piridinil)-1H-imidazol-2-il]benz amida.
MX2016005680A 2013-10-31 2014-10-30 Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea. MX2016005680A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2013227048 2013-10-31
JP2014184172 2014-09-10
PCT/JP2014/079513 WO2015064768A1 (ja) 2013-10-31 2014-10-30 角膜内皮の小胞体細胞死関連疾患治療薬

Publications (1)

Publication Number Publication Date
MX2016005680A true MX2016005680A (es) 2016-10-28

Family

ID=53004360

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005680A MX2016005680A (es) 2013-10-31 2014-10-30 Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea.

Country Status (9)

Country Link
US (2) US11382904B2 (es)
EP (2) EP3064222B1 (es)
JP (1) JPWO2015064768A1 (es)
CA (1) CA2927898C (es)
ES (1) ES2847755T3 (es)
MX (1) MX2016005680A (es)
PL (1) PL3064222T3 (es)
RU (1) RU2712967C2 (es)
WO (1) WO2015064768A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2016106641A (ru) 2013-07-30 2017-09-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтические средства, направленные на ecm эндотелия роговицы
CA2928626C (en) 2013-11-14 2023-03-14 The Doshisha Drug for treating corneal endothelium by promoting cell proliferation or inhibiting cell damage
CA3008113A1 (en) * 2015-12-24 2017-06-29 The Doshisha Drug for treating or preventing disorder caused by tgf-.beta. signals, and application thereof
US11446263B2 (en) 2015-12-24 2022-09-20 The Doshisha Caspase inhibitor-containing drug for treating or preventing disorders caused by TGF-β, and applications thereof
KR101840589B1 (ko) 2016-06-03 2018-03-20 연세대학교 산학협력단 각막이상증 예방 또는 치료용 약학 조성물
EP3593817A4 (en) 2017-03-06 2021-04-07 Tsubota Laboratory, Inc. MODEL FOR THE INDUCTION OF MURINE MYOPIA AND ENDOPLASMATIC RETICULUM STRESS INHIBITOR FOR THE PREVENTION OR SUPPRESSION OF MYOPIA
JPWO2018230712A1 (ja) * 2017-06-16 2020-04-16 学校法人同志社 ＴＧＦ−β阻害剤の新規スクリーニング法
KR102619458B1 (ko) 2017-06-16 2023-12-29 학교법인 도시샤 mTOR 인히비터를 포함하는, 눈의 증상, 장해 또는 질환을 치료 또는 예방하기 위한 의약 및 그 응용
EP3639855A4 (en) * 2017-06-16 2021-03-17 The Doshisha COMPOUNDS HAVING CASPASE INHIBITORING ACTIVITY, PHARMACEUTICAL AGENT CONTAINING THEM FOR THE TREATMENT OR PREVENTION OF SYMPTOMS, DISORDERS OR DISEASES OF CORNEAL ENDOTHELIUM, AND APPLICATION OF SUCH PHARMACEUTICAL AGENT
US11576914B2 (en) 2017-07-26 2023-02-14 The Doshisha Drug for treating or preventing disorder caused by TGF-β signaling, and application thereof
KR20200112834A (ko) * 2017-12-13 2020-10-05 학교법인 도시샤 (t)ew-7197을 포함하는 각막내피 질환을 치료 또는 예방하기 위한 조성물 또는 방법
JP7353631B2 (ja) * 2018-12-14 2023-10-02 国立大学法人 宮崎大学 プローブ、ミトコンドリアの状態判定用キット、ミトコンドリアの状態判定方法及びミトコンドリア機能改善剤のスクリーニング方法
AR122711A1 (es) 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA
WO2022196609A1 (ja) * 2021-03-16 2022-09-22 学校法人慶應義塾 網膜変性抑制用組成物

Family Cites Families (99)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678783B1 (en) 1983-11-04 1995-04-04 Asahi Chemical Ind Substituted isoquinolinesulfonyl compounds
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5654270A (en) 1988-06-28 1997-08-05 La Jolla Cancer Research Foundation Use of fibromodulin to prevent or reduce dermal scarring
US5705609A (en) 1988-06-28 1998-01-06 La Jolla Cancer Research Foundation Decorin fragments inhibiting cell regulatory factors
US5583103A (en) 1988-06-28 1996-12-10 La Jolla Cancer Research Foundation Inhibition of transforming growth factor beta activity
JP2887325B2 (ja) 1988-06-28 1999-04-26 ラ ホヤ キャンサー リサーチ ファウンデーション デコリンによる細胞増殖の抑制
US5571714A (en) 1988-12-22 1996-11-05 Celtrix Pharmaceuticals, Inc. Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use
EP0494264B1 (en) 1989-09-29 1997-06-18 La Jolla Cancer Research Foundation Inhibiting transforming growth factor to prevent accumulation of extracellular matrix
DE69024369T2 (de) 1989-11-22 1996-06-13 Genentech Inc Latenz assoziierte peptide und deren verwendung
WO1991010727A1 (en) 1990-01-22 1991-07-25 La Jolla Cancer Research Foundation Inhibitors of cell regulatory factors
WO1993009228A1 (en) 1991-10-31 1993-05-13 Whitehead Institute For Biomedical Research TGF-β TYPE RECEPTOR cDNAS AND USES THEREFOR
US6008011A (en) 1991-10-31 1999-12-28 Whitehead Institute For Biomedical Research TGF-β type II receptor cDNAs
CA2123418A1 (en) 1991-11-14 1993-05-27 Erkki I. Ruoslahti Inhibitors of cell regulatory factors and methods for preventing or reducing scarring
EP0616536B1 (en) 1991-12-04 1999-03-17 La Jolla Cancer Research Foundation Use of decorin or biglycan for the manufacture of a medicament in the treatment of diabetes-associated pathology
GB9205800D0 (en) 1992-03-17 1992-04-29 British Tech Group Treatment of fibrotic disorders
WO1993019177A1 (en) 1992-03-18 1993-09-30 The General Hospital Corporation FOUR NOVEL RECEPTORS OF THE TGF-β RECEPTOR FAMILY
WO1993019783A1 (en) 1992-04-01 1993-10-14 The Whittier Institute For Diabetes And Endocrinology Methods of inhibiting or enhancing scar formation in the cns
US5821234A (en) 1992-09-10 1998-10-13 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5869462A (en) 1992-09-10 1999-02-09 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of proliferation of vascular smooth muscle cell
US5703047A (en) 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
WO1994009812A1 (en) 1992-10-26 1994-05-11 Kirin Brewery Company, Limited METHOD FOR PRODUCING LARGE LATENT TRANSFORMING GROWTH FACTOR-β COMPLEXES AND LARGE LATENCY ASSOCIATED PEPTIDE
JPH08504763A (ja) 1992-10-29 1996-05-21 セルトリックス ファーマシューティカルズ，インコーポレイテッド 治療薬としてのＴＧＦ−βレセプターフラグメントの使用
EP0667870A4 (en) 1992-10-30 1998-04-01 Hsc Res Dev Lp COMPOSITIONS AND METHODS FOR MODIFYING THE REGULATORY ACTIVITY OF TGF-BETA.
US5830847A (en) 1992-10-30 1998-11-03 Hsc Research & Development Limited Partnership Soluble TGF-β-binding endoglin polypeptides and homodimers
ATE235549T1 (de) 1993-04-30 2003-04-15 Biognostik Ges Antisense oligonukleotide zur behandlung von immunsuppressiven wirkungen von tgf-beta2
EP0737071A1 (en) 1993-06-15 1996-10-16 Il- Yang Pharm. Co., Ltd. Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof
AU8016894A (en) 1993-10-15 1995-05-04 La Jolla Cancer Research Foundation Betaglycan polypeptides having tgf-beta binding activity
US5962427A (en) 1994-02-18 1999-10-05 The Regent Of The University Of Michigan In vivo gene transfer methods for wound healing
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
ATE208494T1 (de) 1994-05-04 2001-11-15 Mount Sinai Hospital Corp Modulatoren der cytokine der tgf-beta überfamilie und verfahren zu ihrer bestimmung
US5772995A (en) 1994-07-18 1998-06-30 Sidney Kimmel Cancer Center Compositions and methods for enhanced tumor cell immunity in vivo
CA2156767A1 (en) 1994-08-25 1996-02-26 Kenichi Matsunaga Binding agent for growth factor
JPH08119984A (ja) 1994-08-31 1996-05-14 Nkk Corp ストレプトミセス属放線菌及びこの菌由来のＴＧＦ−β 阻害剤
US5834248A (en) 1995-02-10 1998-11-10 Millennium Pharmaceuticals Inc. Compositions and methods using rchd534, a gene uregulated by shear stress
US5824655A (en) 1995-02-15 1998-10-20 The University Of Utah Anti-transforming growth factor-β gene therapy
US5824299A (en) 1995-06-22 1998-10-20 President & Fellows Of Harvard College Modulation of endothelial cell proliferation with IP-10
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
JP3421217B2 (ja) 1995-11-20 2003-06-30 麒麟麦酒株式会社 Ｒｈｏ標的タンパク質Ｒｈｏキナーゼ
WO1997031020A1 (en) 1996-02-22 1997-08-28 The General Hospital Corporation METHODS AND COMPOSITIONS FOR ENHANCING CELLULAR RESPONSE TO TGF-β LIGANDS
CA2232682A1 (en) 1996-04-30 1997-11-06 Susan M. Richards Use of prolactin as a tgf-beta antagonist
JPH1067674A (ja) 1996-06-19 1998-03-10 Advanced Sukin Res Kenkyusho:Kk 細胞外マトリツクスの異常蓄積抑制剤
ATE412751T1 (de) 1996-07-24 2008-11-15 Chugai Pharmaceutical Co Ltd Menschliche tak1 und für diese kodierende dna
US5807708A (en) 1996-07-30 1998-09-15 Millennium Pharmaceuticals, Inc. Conservin nucleic acid molecules and compositions
WO1998007735A1 (en) 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Pancreas-derived plasminogen activator inhibitor
US6017755A (en) 1996-08-22 2000-01-25 Hsc Research & Development Limited MADR2 tumour suppressor gene
AU3215597A (en) 1996-08-30 1998-03-19 Biomeasure Incorporated Method of inhibiting fibrosis with a somatostatin agonist
DE69734894T2 (de) 1996-10-25 2006-07-20 Ethicon, Inc. Testverfahren für antifibrotischen wirkstoff
WO1998024466A1 (en) * 1996-12-05 1998-06-11 Alcon Laboratories, Inc. THE USE OF INHIBITORS OF TGF-β'S FUNCTIONS TO AMELIORATE OCULAR PATHOLOGY
US5948639A (en) 1997-04-10 1999-09-07 Millennium Pharmaceuticals, Inc. TGF-β pathway genes
BR9808934A (pt) 1997-04-18 2000-08-01 Biogen Inc Proteìnas de fusão de região constante de receptor/imunoglobulina tgf-beta do tipo ii
JPH10295381A (ja) 1997-04-23 1998-11-10 Seibutsu Bunshi Kogaku Kenkyusho:Kk 新規シグナル伝達因子、およびそれをコードする遺伝子
EP0983360A1 (en) 1997-05-20 2000-03-08 Ludwig Institute For Cancer Research Smad7 and uses thereof
US6365711B1 (en) 1997-05-28 2002-04-02 President And Fellows Of Harvard College Methods and reagents for modulating TGF-β superfamily signalling
CA2291754C (en) 1997-06-02 2009-11-17 Vlaams Interuniversitair Instituut Voor Biotechnologie Smad-interacting polypeptides and their use
US6270994B1 (en) 1997-06-13 2001-08-07 Japanese Foundation For Cancer Research Smad6 and uses thereof
WO1999020620A1 (fr) 1997-10-22 1999-04-29 Nippon Shinyaku Co Ltd Derive d'isoquinoleine et medicament
CA2324476A1 (en) 1998-03-27 1999-10-07 Eli Lilly And Company Treatment and prevention of vascular disease
ATE324362T1 (de) 1998-05-25 2006-05-15 Santen Pharmaceutical Co Ltd Neue vinylbenzolderivate
ES2146552B1 (es) * 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
MXPA02009695A (es) 2000-04-07 2003-03-27 Sang Geon Kim Uso profilactico y terapeutico de oltipraz como un agente antifibrotico y anticirrotico en el higado y composicion farmaceutica que contiene oltipraz.
AR035792A1 (es) 2001-03-23 2004-07-14 Bayer Corp Compuestos de n-(4-quinazolinil)-n-(1h-indazol-5-il) amina, inhibidor de la rho-quinasa, su uso para la fabricacion de un medicamento y metodo para prepararlo
US20030125344A1 (en) 2001-03-23 2003-07-03 Bayer Corporation Rho-kinase inhibitors
JP4204326B2 (ja) 2001-04-11 2009-01-07 千寿製薬株式会社 視覚機能障害改善剤
WO2002100833A1 (fr) 2001-06-12 2002-12-19 Sumitomo Pharmaceuticals Company, Limited Inhibiteurs de rho kinase
WO2003059913A1 (en) 2002-01-10 2003-07-24 Bayer Healthcare Ag Roh-kinase inhibitors
ATE381557T1 (de) 2002-01-23 2008-01-15 Bayer Pharmaceuticals Corp Rho-kinase inhibitoren
AU2003229305A1 (en) * 2002-05-17 2003-12-02 Scios, Inc. TREATMENT OF FIBROPROLIFERATIVE DISORDERS USING TGF-Beta INHIBITORS
EP1541559A4 (en) 2002-07-22 2007-08-22 Asahi Kasei Pharma Corp 5-SUBSTITUTED ISOQUINOLINE DERIVATIVE
CA2400996A1 (en) 2002-09-03 2004-03-03 Lisa Mckerracher 1,4-substituted cyclohexane derivatives
US7160894B2 (en) 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
EP1644365A2 (en) 2003-07-02 2006-04-12 Biofocus Discovery Ltd Pyrazine and pyridine derivatives as rho kinase inhibitors
US8158589B2 (en) 2003-08-22 2012-04-17 Proyecto Biomedicine Cima, S.L. Peptides with the capacity to bind to transforming growth factor β1 (TGF-β1)
US20050182061A1 (en) 2003-10-02 2005-08-18 Jeremy Green Phthalimide compounds useful as protein kinase inhibitors
JP2007507549A (ja) 2003-10-06 2007-03-29 グラクソ　グループ　リミテッド キナーゼ阻害剤としての１，６，７−三置換アザベンゾイミダゾールの調製
US7547779B2 (en) 2003-10-06 2009-06-16 Glaxo Group Limited Preparation of 1,6-disubstituted azabenzimidazoles as kinase inhibitors
EP1689393A4 (en) 2003-10-06 2008-12-17 Glaxo Group Ltd PREPARATION OF 1,7-DISUBSTITUTED AZABENZIMIDAZOLES AS KINASE INHIBITORS
CN1863779B (zh) 2003-10-15 2010-05-05 宇部兴产株式会社 吲唑衍生物
JP2007008816A (ja) 2003-10-15 2007-01-18 Ube Ind Ltd 新規イソキノリン誘導体
JP2007015928A (ja) 2003-10-15 2007-01-25 Ube Ind Ltd 新規オレフィン誘導体
JP2007523202A (ja) 2004-02-24 2007-08-16 ビオアクソン・テラプティーク・インコーポレーテッド ４置換ピペリジン誘導体
CN101014597A (zh) 2004-04-02 2007-08-08 沃泰克斯药物股份有限公司 可用作rock和其他蛋白激酶抑制剂的吖吲哚
CN101056656A (zh) * 2004-09-15 2007-10-17 哈佛大学校长及研究员协会 在治疗肥胖症和糖尿病中降低er应力
EP1829876A4 (en) 2004-11-26 2009-04-01 Asahi Kasei Pharma Corp NITROGENIC TRICYCLIC COMPOUND
KR20080012258A (ko) * 2005-02-10 2008-02-11 리전츠 오브 더 유니버스티 오브 미네소타 시각장애를 치료하는 방법
WO2006096011A1 (en) 2005-03-08 2006-09-14 Medigenes Co., Ltd. PHARMACEUTICAL COMPOSITION FOR TREATING AVELLINO CORNEA DYSTROPHY COMPRISING AN ANTIBODY AGAINST TGF-β
KR101149954B1 (ko) 2005-08-30 2012-06-01 아사히 가세이 파마 가부시키가이샤 술폰아미드 화합물
ZA200804496B (en) * 2005-12-16 2009-09-30 Alcon Inc Control of intraocular pressure using ALK5 modulation agents
US8946201B2 (en) 2007-08-27 2015-02-03 Saint Louis University Methods for inhibiting TGF-β
US20100087486A1 (en) * 2008-05-30 2010-04-08 Hiroshi Nakamura Methods for using tgf-b receptor inhibitors or activin-like kinase (alk) 5 inhibitors a-83-01 and sb-431542 to treat eye disease and wound healing conditions
JP2012524073A (ja) 2009-04-17 2012-10-11 スムマ ヘルス システムズ エルエルシー 眼球瘢痕化を抑制するための形質転換成長因子−β受容体阻害剤の使用
US20130288985A1 (en) 2010-07-15 2013-10-31 The Schepens Eye Research Institute Inc. Compositions and methods of treatment of corneal endothelium disorders
EP2408113B1 (en) 2010-07-16 2013-03-06 ST-Ericsson SA Delta-sigma analog-to-digital converter and method for operating the same.
KR101258166B1 (ko) * 2010-09-01 2013-04-25 연세대학교 산학협력단 Ｔｇｆｂｉ 유전자 변이 각막 이상증의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법
US9752118B2 (en) 2011-12-06 2017-09-05 Astellas Institute For Regenerative Medicine Method of directed differentiation producing corneal endothelial cells from neural crest stem cells by PDGFB and DKK2, compositions thereof, and uses thereof
US20150044178A1 (en) 2011-12-28 2015-02-12 Kyoto Prefectural Public University Corporation Normalization of culture of corneal endothelial cells
JP5959291B2 (ja) 2012-04-26 2016-08-02 積水化成品工業株式会社 保冷容器
RU2016106641A (ru) 2013-07-30 2017-09-01 Киото Прифекчурал Паблик Юниверсити Корпорэйшн Терапевтические средства, направленные на ecm эндотелия роговицы
JP5847227B2 (ja) 2014-04-10 2016-01-20 株式会社大一商会 遊技機

Also Published As

Publication number Publication date
EP3064222B1 (en) 2020-10-21
CA2927898C (en) 2021-11-16
RU2016121150A (ru) 2017-12-05
EP3064222A1 (en) 2016-09-07
EP3064222A4 (en) 2017-07-19
EP3804760A1 (en) 2021-04-14
WO2015064768A1 (ja) 2015-05-07
US11382904B2 (en) 2022-07-12
CA2927898A1 (en) 2015-05-07
RU2016121150A3 (es) 2018-08-20
US20220296580A1 (en) 2022-09-22
RU2712967C2 (ru) 2020-02-03
US20160296505A1 (en) 2016-10-13
ES2847755T3 (es) 2021-08-03
JPWO2015064768A1 (ja) 2017-03-09
PL3064222T3 (pl) 2021-04-19

Similar Documents

Publication Publication Date Title
MX2016005680A (es) Farmaco terapeutico para enfermedades relacionadas con la muerte celular del reticulo endoplasmico en el endotelio de cornea.
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
TN2019000136A1 (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12016502382A1 (en) Substituted indazole compounds as irak4 inhibitors
PH12017500166A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors
PH12015502116A1 (en) Biaryl amide compounds as kinase inhibitors
TN2016000268A1 (en) N-azaspirocycloalkane substituted n-heteroaryl compounds and compositions for inhibiting the activity of shp2.
MX2016014305A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
GEP20196949B (en) 2-amino-6-(difluoromethyl)-5, 5-difluoro-6-phenyl-3, 4, 5, 6-tetra- hydropyridines as bace1 inhibitors
GEP20186892B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2013011908A (es) Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank.
PH12014501967A1 (en) Benzodioxanes in combination with other actives for inhibiting leukotriene production
BR112017009647A2 (pt) 2-amino-3,5-difluoro-3,6-dimetil-6-fenil-3,4,5,6-tetraidropiridinas como inibidoras da bace1 para tratar a doença de alzheimer
NZ704266A (en) Inhibitors of alpha-crystallin aggregation for the treatment for cataract
MX2017006447A (es) Agentes antifungicos.
MX341565B (es) 3-amino-piridinas como agonistas de receptor de acido biliar acoplado a proteina g1 (gpbar1).
MX2013008056A (es) 1,4-oxazepinas como inhibidores de beta-secretasa 1 (bace1) y/o beta-secretasa 2 (bace2).
PH12015502365B1 (en) Bace1 inhibitors
NZ598750A (en) Therapeutic agent for mood disorders
WO2011107608A8 (en) Heterocyclic amides as rock inhibitors
PH12017500747B1 (en) Heterocyclic compound
MX2014002395A (es) Inhibidores de rock suaves, novedosos.
NZ598754A (en) Therapeutic agent for anxiety disorders
GB201107576D0 (en) Novel compounds and methods for use in medicine